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The p.Thr1406Asn (rs1047891) polymorphism of the carbamoyl-phosphate synthetase 1 (CPS1) gene 
has been linked to functional consequences affecting the downstream availability of the nitric oxide 
precursor L-arginine. L-arginine concentrations are decreased in preterm infants with necrotizing 
enterocolitis (NEC). In this multicenter prospective study, we investigated the association of the 
p.Thr1406Asn polymorphism with NEC in 477 preterm infants (36 cases of NEC) from 4 European 
neonatal intensive care units (Maastricht, Las Palmas de Gran Canaria, Mantova, and Milan). Allele 
and genotype frequencies of the p.Thr1406Asn polymorphism did not significantly differ between the 
infants with and without NEC. In contrast, the minor A-allele was significantly less frequent in the group 
of 64 infants with the combined outcome NEC or death before 34 weeks of corrected gestational age 
than in the infants without the outcome (0.20 vs. 0.31, P = 0.03). In addition, a significant negative 
association of the A-allele with the combined outcome NEC or death was found using the dominant 
(adjusted odds ratio, aOR: 0.54, 95% CI 0.29–0.99) and the additive (aOR 0.58, 95% CI 0.36–0.93) 
genetic models. In conclusion, our study provides further evidence that a functional variant of the CPS1 
gene may contribute to NEC susceptibility.
Necrotizing enterocolitis (NEC) remains a significant cause of morbidity and mortality in neonatal intensive care 
units. Although several predisposing factors have been identified, the exact etiology of NEC is yet elusive. The 
combination of genetic predisposition, immaturity of gastrointestinal motility, digestive ability, intestinal barrier 
function, immune defense and microcirculatory regulation accompanied by a strong likelihood of abnormal 
microbial colonization in the intestine, leads to a confluence of predisposing factors1–9.
Nitric oxide (NO) has received increasing attention in the pathophysiology of NEC, as it participates in the 
regulation of intestinal blood flow and plays a key role in the maintenance of mucosal integrity, intestinal bar-
rier function, and post-injury intestinal repair10–12. NO is generated by NO synthase (NOS) during the enzy-
matic conversion of L-arginine to L-citrulline. The NOS substrate L-arginine is an essential amino acid for young 
mammals13,14. Metabolic and molecular studies indicate that the underdevelopment of intestinal arginine syn-
thesis may be primarily responsible for remarkably low plasma arginine concentrations in preterm neonates14,15. 
Several studies demonstrated that plasma arginine concentrations are even more decreased in preterm infants 
with NEC14,16–19. Moreover, data from two small randomized controlled studies16,20, pooled in a meta-analysis21, 
suggest that arginine supplementation reduces the incidence of NEC in preterm infants.
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Arginine is a urea cycle intermediate. The first step in the urea cycle occurs inside the mitochondrion and is 
catalyzed by the enzyme, carbamoyl-phosphate synthetase I (CPS1, EC 6.3.4.16)22. CPS1 deficiency in humans 
is a rare autosomal recessive inborn error of the urea cycle leading to hyperammonemia. Deficiency can be pri-
mary, due to mutations in the CPS1 gene (OMIM 608307, HGNC:2323) or secondary, due to the lack of the 
essential cofactor N-acetyl-L-glutamate22. In addition, a number of functional single nucleotide polymorphisms 
(SNPs) have been identified in the CPS1 gene22–24. One of those SNPs (p.Thr1406Asn also published as T1405N; 
rs1047891 formerly designated as rs7422339) has been linked to functional consequences affecting the down-
stream availability of urea-cycle intermediates, including L-arginine22–24. The SNP p.Thr1406Asn is a C-to-A 
nucleotide transversion (c.4217 C > A) in exon 36, which results in the substitution of asparagine (Asn) for thre-
onine (Thr) in the critical N-acetylglutamate-binding domain22,25. The C-encoded Thr form of the polymorphism 
is considered the evolutionarily conserved version and the less frequent, A-encoded, Asn variant appears to be a 
relatively new, gain-of-function mutation15,25. It has been suggested that the A-allele may confer an advantage in 
terms of NO production, especially under conditions of environmental stress15. Previous studies demonstrated 
the association of the CPS1 p.Thr1406Asn genotype with clinical situations where endogenous NO production 
is critically important, such as persistent pulmonary hypertension of the newborn15, pulmonary hypertension 
following surgical repair of congenital heart defects26, and hepatic veno-occlusive disease after bone marrow 
transplantation23.
Several years ago, we reported in a retrospective series of 17 preterm infants with NEC and 34 controls that 
patients with NEC showed an underrepresentation of the A-encoded variant of the p.Thr1406Asn polymorphism 
of CPS1 27. Those results suggested that the A-allele conferred protection against NEC and warranted confirma-
tion using a prospective design and larger sample size. Herein we report the results of such study, involving 477 
preterm infants (36 cases of NEC) from four neonatal intensive care units located in three different European 
countries (Spain, Italy, and the Netherlands). Since death in the first weeks of life is a competing outcome for 
NEC, we also analyzed the association of the p.Thr1406Asn polymorphism with the combined outcome NEC or 
death before 34 weeks of corrected gestational age(GA).
Methods
Patients. The study was approved by the Institutional Review Boards (IRBs) of the Maastricht University 
Medical Center (the Netherlands, registration number MEC 04–140), Hospital Universitario Materno-Infantil 
de Canarias (Las Palmas de Gran Canaria, Spain), Carlo Poma Hospital (Mantova, Italy) and Ospedale Maggiore 
Policlinico (Milan, Italy). The study was conducted according to institutional and IRB guidelines and regulations 
and registered in ClinicalTrials.gov Protocol Registration System (NCT00554866, ID 07-2-018, November 6, 
2007). The manuscript was drafted according to the STROBE statement (http://www.strobe-statement.org/). All 
infants with a GA ≤ 30 weeks and birth weight (BW) ≤ 1500 g born between 1st July 2007 and 30th June 2012 
and admitted to the level III neonatal intensive care unit of the above mentioned centers (Carlo Poma Hospital: 
inclusion until 31st December 2010; Ospedale Maggiore Policlinico: inclusion from 1st March 2011) were eligible 
for participation in the study. Written informed consent from the parents was obtained. As reported in a previous 
study, buccal cell samples were obtained from 96 healthy term infants (25 in Maastricht, 31 in Las Palmas de Gran 
Canaria and 40 in Mantova)28.
Definition of clinical characteristics and outcomes. Data on clinical characteristics and outcomes 
were obtained from the medical records. GA was determined by the last menstrual period and early ultrasounds 
(before 20 weeks of gestation). Small for GA was defined as BW for GA below the sex-specific 10th percentile. 
Chorioamnionitis was defined as every clinical suspicion of infection of the chorion, amnion, amniotic fluid, 
placenta, or a combination as judged by the obstetrician. Prolonged rupture of membranes was defined as rupture 
of membranes > 24 hours before delivery. Prenatal exposure to a single course of antenatal steroids was defined 
as two doses of betamethasone administered 24 h apart and exposure to a partial course of antenatal steroids was 
defined as administration of a single dose of betamethasone < 24 h prior to delivery.
NEC was defined as Bell stage II disease or greater. At the conclusion of the study, all cases of NEC were 
reviewed in a blinded fashion by a panel of 4 investigators of the study. Cases of spontaneous intestinal perfo-
ration (i.e., without pathologic evidence of NEC) were excluded from the investigation. Since it was considered 
that some infants who died in the first weeks may have developed NEC if they had survived, we also analyzed the 
composite outcome of NEC or death before 34 weeks of corrected GA.
Respiratory distress syndrome (RDS) was defined as requirement for oxygen supplementation or respiratory 
support due to tachypnea, grunting, nasal flaring, retractions, or cyanosis. Bronchopulmonary dysplasia (BPD) 
was defined as a supplemental oxygen requirement at 36 weeks of corrected GA to maintain oxygen satura-
tion > 90% 29. Arterial hypotension was defined as the need for volume expansion or inotropic support. Patent 
ductus arteriosus (PDA) was defined as a requirement for indomethacin or ibuprofen and/or surgical ligation. 
A diagnosis of sepsis required signs of generalized infection, a positive blood culture, and antibiotic therapy. 
Intraventricular hemorrhage (IVH) was classified by using the 4-level grading system30. Grade < 2 IVHs were not 
included in the analysis. Retinopathy of prematurity (ROP) was defined as stage II or higher.
Samples and genotyping. Buccal cell samples for DNA testing were obtained with a sterile OmniSwab 
(Whatman), and collected in Eppendorf sterile PCR tubes and stored at − 80 °C until further analysis. The sam-
ples obtained in Spain and Italy were transported on dry ice to Maastricht where all the analyses were performed. 
DNA was extracted using standard methods and stored at − 20 °C until genotyping. A 214-bp fragment encom-
passing the p.Thr1406Asn polymorphism in exon 36 of the CPS1 gene was amplified using polymerase chain 
reaction (PCR). Primers used were (forward) GCM357 5′ -TAAATGCAGCTGTTTGCCAC-3′ and (reverse) 
GCM358 5′ -GACTTGCAATCAAGTAAGGTGAAA-3′ . The PCR mix consisted of 1X GeneAmp PCR Buffer 
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II (Perkin-Elmer, Branchburg, NJ), 0.2 mM deoxyribonucleoside triphosphate (Pharmacia Biotech, Bridgewater, 
NJ), 1.5 mM MgCl2 (Perkin-Elmer, Branchburg, NJ), 250 nM of both primers, and 0.025 U/μ L of AmpliTaq Gold 
(Perkin-Elmer, Branchburg, NJ). Thermocycling conditions started with an initial denaturation of 10 min 95 °C, 
followed by 35 cycles of 95 °C (45 s), 55 °C (45 s), 72 °C (45 s), and ended with a final extension step of 10 min at 
72 °C. The PCR product was purified and directly sequenced using the reverse primer.
Statistical Analysis. Sample size was calculated based on data from our previous study27. Given an expected 
population incidence of NEC of 5%, expected frequencies for CC homozygosity of 0.7 (NEC group) and 0.4 (con-
trol group), alpha level = 0.05, and power of 0.8, 440 infants were needed to detect an odds ratio (OR) significantly 
different from 1.
Categorical variables were expressed as counts or percentages and compared using the chi-square test. 
Continuous variables were expressed as mean (SD) if they followed a normal distribution and compared 
using unpaired, two-sided t-test. If not normally distributed, continuous variables were expressed as median 
values (interquartile range, IQR; 25th–75th percentile) and compared using the Mann-Whitney U test. The 
Kolmogorov-Smirnov test was used to test for normal distribution of continuous data.
Differences in allelic frequencies and genotype distributions between the investigated populations, as well 
as Hardy–Weinberg equilibrium (HWE) for genotype distribution were assessed using a chi-square test. The 
Hardy–Weinberg law states that q2 + 2pq + p2 = 1, where p and q are allele frequencies in a two-allele system. 
Logistic regression analysis was used to compute the ORs and their 95% confidence intervals (CI) for NEC and 
the combined outcome NEC or death before 34 weeks of corrected GA based on genotype after accounting for the 
covariates which were significantly different between the groups and are known risk factors for developing NEC. 
Different genetic models were used to analyze the effect of the risk allele, including the general allelic (multiplica-
tive or codominant model), dominant, recessive and additive models. Assuming a genetic penetrance parameter 
γ (γ > 1), a multiplicative model indicates that the risk of disease is increased γ -fold with each additional copy of 
the risk allele; an additive model indicates that risk of disease is increased γ -fold for the genotype with one copy of 
the risk allele and 2γ -fold for the genotype with two copies of the risk allele; a common recessive model indicates 
that two copies of the risk allele are required for a γ -fold increase in disease risk, and a common dominant model 
indicates that either one or two copies of the risk allele are required for a γ -fold increase in disease risk31. The 
major allele was considered as a reference and the interactions were tested in the different models by multivaria-
ble logistic regression model. All the statistical analyses were performed using IBM SPSS Statistics for Windows, 
Version 22.0. (IBM Corporation, Armonk, NY, USA) and conducted at the P < 0.05 level of significance.
Results
Patient characteristics. From 615 eligible infants, 477 (36 with NEC Bell stage II or greater) were included 
in the study (Fig. 1). Stage II NEC was present in 23 infants and stage III in 13 infants. In 21 cases surgery was 
required. The median age at the onset of NEC was 20 days (range 4–87, IQR 12–31). Nine of the cases of NEC 
occurred in Maastricht (5 stage II NEC, 4 stage III NEC), 16 in Las Palmas (9 stage II NEC, 7 stage III NEC), and 
11 in Italy (9 stage II NEC, 2 stage III NEC). Single intestinal perforation was present in 5 infants (1 in Maastricht, 
4 in Italy). Demographic and clinical characteristics of the infants with and without NEC are shown and com-
pared in Table 1. Mean GA, mean BW and median Apgar score at 1 min of infants with NEC were significantly 
lower than in infants without NEC. In addition, infants with NEC showed a higher incidence of vaginal delivery, 
mechanical ventilation, BPD, hypotension, IVH, PVL, PDA, ROP and mortality. We adjusted for GA, BW, Apgar 
score at 1 min, mechanical ventilation, hypotension, and PDA in the subsequent logistic regression analysis.
The demographic and clinical characteristics of the infants with and without the combined outcome NEC or 
death before 34 weeks of corrected GA are shown and compared in Table 2. Mean GA, mean BW and median 
Figure 1. Flowchart of study participants. 
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NEC –yes (n = 36) n data missing NEC – no (n = 441) n data missing P value
Birth weight (g) 844 (SD 216) 0 1016 (SD 266) 0 0.000
Gestational age (wks) 26.7 (SD 1.9) 0 27.9 (SD 1.9) 0 0.000
Male sex 17 (47.2) 0 238 (54.0) 0 0.419
Prenatal steroids 28 (80.0) 1 375 (88.2) 16 0.361
Preecclampsia 3 (8.6) 1 68 (15.6) 5 0.264
Chorioamnionitis 3 (8.3) 0 58 (13.3) 5 0.393
PROM 6 (16.7) 0 118 (27.2) 7 0.169
Vaginal delivery 17 (58.6) 0 147 (43.2) 2 0.042
Apgar (1 min) 5 [3–7] 1 6 [4–8] 5 0.026
Apgar (5 min) 8 [6–9] 1 8 [7–9] 6 0.114
RDS 30 (83.3) 0 378 (85.9) 1 0.671
Mechanical vent. 32 (88.9) 0 279 (64.0) 5 0.002
BPD 21 (58.3) 0 137 (31.3) 3 0.001
Hypotension 26 (72.2) 0 175 (40.1) 5 0.000
Sepsis 23 (67.6) 2 227 (51.7) 2 0.073
IVH 16 (44.4) 0 110 (25.1) 3 0.012
PVL 4 (11.1) 0 14 (3.2) 4 0.017
PDA 25 (71.4) 1 233 (53.2) 3 0.037
ROP 13 (41.9) 5 85 (20.5) 27 0.006
Mortality 8 (22.2) 0 42 (9.5) 0 0.017
Death before 34 wks 5 (13,9) 0 29 (6.6) 0 0.101
Table 1.  Baseline characteristics and neonatal complications in preterm infants with and without NEC. 
Results are expressed as mean (SD), median [interquartile range] or absolute numbers of patients (percentage). 
NEC: necrotizing enterocolitis (≥ stage II); PROM: prolonged rupture of membranes; RDS: respiratory  
distress syndrome; BPD: bronchopulmonary dysplasia; IVH: intraventricular hemorrhage (≥ grade 2);  
PVL: periventricular leukomalacia; PDA: patent ductus arteriosus; ROP: retinopathy of prematurity (≥ stage II).
NEC/death-yes (n = 65) n data missing NEC/death-no (n = 412) n data missing P-value
Birth weight (g) 818 (SD 230) 0 1032 (SD 261) 0 0.000
Gestational age (wks) 26.4 (SD 2.0) 0 28.1 (SD 1.8) 0 0.000
Male sex 34 (52.3) 0 221 (53.6) 0 0.841
Prenatal steroids 51 (81.0) 2 352 (88.7) 15 0.223
Preecclampsia 6 (9.4) 1 65 (16.0) 5 0.170
Chorioamnionitis 11 (17.2) 1 50 (12.3) 4 0.274
PROM 15 (23.8) 2 109 (26.8) 5 0.618
Vaginal delivery 34 (52.3) 0 142 (34.6) 2 0.006
Apgar (1 min) 5 [3–6] 1 6 [5–8] 6 0.000
Apgar (5 min) 8 [6–8] 1 8 [7–9] 6 0.000
RDS 54 (83.1) 0 354 (86.1) 1 0.513
Mechanical vent. 60 (92.3) 0 251 (61.7) 5 0.000
BPD 24 (37.5) 1 134 (32.7) 2 0.447
Hypotension 52 (80.0) 0 149 (36.6) 5 0.000
Sepsis 38 (60.3) 2 212 (51.7) 2 0.202
IVH 31 (48.4) 1 95 (23.2) 2 0.000
PVL 5 (7.8) 1 13 (3.2) 3 0.072
PDA 45 (71.4) 2 213 (52.0) 2 0.004
ROP 13 (25.0) 13 85 (21.6) 19 0.581
Table 2.  Baseline characteristics and neonatal complications in preterm infants with and without the 
combined outcome NEC or death before 34 wks of corrected gestational age. Results are expressed as 
mean (SD), median [interquartile range] or absolute numbers of patients (percentage). NEC: necrotizing 
enterocolitis (≥ stage II); PROM: prolonged rupture of membranes; RDS: respiratory distress syndrome; 
BPD: bronchopulmonary dysplasia; IVH: intraventricular hemorrhage (≥ grade 2); PVL: periventricular 
leukomalacia; PDA: patent ductus arteriosus; ROP: retinopathy of prematurity (≥ stage II).
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Apgar score at 1 and 5 min of infants with NEC or death were significantly lower than in infants without the 
combined outcome. In addition, infants with the combined outcome NEC or death showed a higher incidence 
of vaginal delivery, mechanical ventilation, hypotension, IVH and PDA. We adjusted for GA, BW, Apgar score 
after at 1 and 5 min, mechanical ventilation, hypotension and PDA in the subsequent logistic regression analysis.
Analysis of genotypes. Allele and genotype frequencies of the p.Thr1406Asn polymorphism in the total 
preterm population did not significantly differ from the allele and genotype frequencies observed in the popu-
lation of 96 healthy term infants (P = 0.925, Table 3)28. The distribution of the genotypes p.Thr1406Asn did not 
fulfill Hardy-Weinberg criteria in the preterm population. The minor allele frequency (MAF) in the NEC group 
(0.208) was not significantly different from the MAF among the infants without NEC (0.303, P = 0.09; Table 4). 
The MAF in the NEC group with the combined outcome NEC or death before 34 weeks (0.200) was significantly 
different from the MAF among the infants without the outcome (0.311, P = 0.03; Table 5).
We further analyzed the effect of the CPS1 p.Thr1406Asn polymorphism on the occurrence of NEC and 
NEC or death under different genetic models. As shown in Table 4, logistic regression analysis could not detect 
any significant association between the p.Thr1406Asn polymorphism and NEC in any of the genetic models. In 
contrast, the dominant and the additive model showed a negative significant association of the A-allele of the 
CPS1 p.Thr1406Asn polymorphism with the combined outcome NEC or death before 34 weeks of corrected GA 
(Table 5). Finally, we analyzed the correlation of the CPS1 p.Thr1406Asn polymorphism genotype with other 
neonatal outcomes. As shown in Table 6, we could not find any significant association.
Discussion
This is one of the largest prospective studies investigating the association of a SNP with NEC. Our study could not 
detect a significant association between the p.Thr1406Asn genotype of the CPS1 gene and the risk of developing 
NEC in very preterm infants (GA ≤ 30 weeks and BW ≤ 1500 g). However, when the combined outcome NEC or 
death before 34 weeks of corrected GA was analyzed, it was observed that the minor A-allele of the p.Thr1406Asn 
polymorphism was significantly less frequent in the group of infants who developed NEC or died than in those 
who survived without NEC. In addition, a significant negative association of the A-allele with the combined out-
come NEC or death was found using the dominant and the additive genetic models.
In our previous retrospective case-control study, we examined the relationship between the CPS1 
p.Thr1406Asn polymorphism and the presence of NEC in preterm infants and we found that patients with NEC 
showed an overrepresentation of the C-encoded variant of the CPS1 27. Consequently, the A-encoded variant of 
the p.Thr1406Asn polymorphism was underrepresented in the infants with NEC. However, although the cases 
and the controls were well matched for GA and BW, when adjusted for these two known risk factors for NEC, 
the association between NEC and the p.Thr1406Asn polymorphism did not remain significant27. In the present 
Population CC CA AA MAF
Total study group (n = 477) 248 (52.0) 176 (36.9) 53 (11.1) 0.296
Term control group (n = 96)34 52 (54.2) 34 (35.4) 10 (10.4) 0.281
Table 3.  Distribution of the CPS1 p.Thr1406Asn polymorphism genotypes in preterm and term 
infants. Results are expressed as absolute numbers of patients (percentage). CC denotes homozygosity for 
the C-encoded CPS1 p.Thr1406Asn polymorphism variant; AA homozygosity for the A-encoded CPS1 
p.Thr1406Asn polymorphism variant; CA heterozygosity for CPS1 p.Thr1406Asn polymorphism; MAF: minor 
allele frequency.
Model Genotype
NEC-no 
(n = 441) N (%)
NEC-yes 
(n = 36) N (%) OR (95% CI) P-value aOR (95% CI) P-value
Codominant CC 226 (51.2) 22 (61.1) 1 (reference) 1 (reference)
CA 163 (37.0) 13 (36.1) 0.82 (0.40–1.67) 0.59 0.87 (0.41–1.88) 0.73
AA 52 (11.8) 1 (2.8) 0.20 (0.03–1.50) 0.12 0.21 (0.03–1.66) 0.14
Dominant CC 226 (51.2) 22 (61.1) 1 (reference) 1 (reference)
AA_CA 215 (48.8) 14 (38.9) 0.67 (0.33–1.34) 0.26 0.71 (0.34–1.48) 0.36
Recessive CC_CA 389 (88.2) 35 (97.2) 1 (reference) 1 (reference)
AA 52 (11.8) 1 (2.8) 0.21 (0.03–1.59) 0.13 0.23 (0.03–1.71) 0.15
Additive 0.64 (0.36–1.11) 0.11 0.66 (0.36–1.19) 0.17
MAF 0.303 0.208 0.09
Table 4.  Distribution of the CPS1 p.Thr1406Asn polymorphism genotypes in preterm infants with and 
without NEC. OR; odds ratio; aOR: odds ratio adjusted for birth weight, gestational age, Apgar score after 
1 minute, mechanical ventilation, hypotension and PDA; CI: confidence interval; MAF: minor allele frequency; 
CC denotes homozygosity for the C-encoded CPS1 p.Thr1406Asn polymorphism variant; AA homozygosity 
for the A-encoded CPS1 p.Thr1406Asn polymorphism variant; CA heterozygosity for CPS1 p.Thr1406Asn 
polymorphism.
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prospective cohort study, we observed that the A-allele was less frequent in the infants with NEC in a propor-
tion close to reach statistical significance (P = 0.09). Moreover, only one infant with NEC was homozygous for 
the A-allele. Nevertheless, none of the genetic models could demonstrate a statistically significant association 
between the p.Thr1406Asn genotype and NEC.
An important issue in designing studies involving high-risk patients is the selection of an appropriate primary 
outcome when death is a competing outcome32. In this situation, some patients will die before the outcome of 
interest can occur. For this reason, a composite outcome including death is often used when complications of 
prematurity such as BPD or NEC are studied32. Since the onset of ‘classical’ NEC takes place around the end of the 
Model Genotype
NEC/death-no 
(n = 412) N (%)
NEC/death-yes 
(n = 65) N (%) OR (95% CI) P-value aOR (95% CI) P-value
Codominant CC 206 (50.0) 42 (64.6) 1 1
CA 156 (37.9) 20 (30.8) 0.63 (0.36–1.11) 0.11 0.63 (0.33–1.20) 0.11
AA 50 (12.1) 3 (4.6) 0.29 (0.09–0.99) 0.05 0.28 (0.08–1.02) 0.05
Dominant CC 206 (50.0) 42 (64.6) 1 1
AA_CA 206 (50.0) 23 (35.4) 0.55 (0.32–0.94) 0.03 0.54 (0.29–0.99) 0.04
Recessive CC_CA 362 (87.9) 62 (95.4) 1 1
AA 50 (12.1) 3 (4.6) 0.35 (0.11–1.16) 0.09 0.33 (0.10–1.18) 0.09
Additive 0.59 (0.38–0.91) 0.02 0.58 (0.36–0.93) 0.03
MAF 0.311 0.2 0.03
Table 5.  Distribution of the CPS1 p.Thr1406Asn polymorphism genotypes in preterm infants with 
and without the combined outcome NEC or death before 34 wks of corrected gestational age. OR; odds 
ratio; aOR:odds ratio adjusted for birth weight, gestational age, Apgar score after 1 minute, Apgar score after 
5 minute, mechanical ventilation, hypotension and PDA; CI: confidence interval; MAF: minor allele frequency; 
CC denotes homozygosity for the C-encoded CPS1 p.Thr1406Asn polymorphism variant; AA homozygosity 
for the A-encoded CPS1 p.Thr1406Asn polymorphism variant; CA heterozygosity for CPS1 p.Thr1406Asn 
polymorphism.
Outcome No. of infants CC CA AA P-value
Gestational age (wks) 477 27.7 (SD 2.0) 28.0 (SD 1.7) 28.1 (SD 1.9) 0.16
Birth weight (g) 477 984 (SD 269) 1018 (SD 260)
1043 (SD 
277) 0.23
RDS yes 408 205 (50.3) 158 (38.7) 45 (11.0) 0.14
no 68 42 (61.7) 18 (26.5) 8 (11.8)
BPD yes 158 89 (56.3) 53 (33.5) 16 (10.1) 0.39
no 316 157 (49.7) 122 (38.6) 37 (11.7)
BPD or death before 36 
weeks yes 187 109 (58.3) 59 (31.6) 19 (10.2) 0.07
no 288 137 (47.6) 117 (40.6) 34 (11.8)
Hypotension yes 201 103 (51.2) 77 (38.3) 21 (10.4) 0.84
no 271 141 (52.0) 98 (36.2) 32 (11.8)
Sepsis yes 250 132 (52.8) 86 (34.4) 32 (12.8) 0.32
no 223 113 (50.7) 89 (39.9) 21 (9.4)
IVH yes 126 68 (54.0) 42 (33.3) 16 (12.7) 0.53
no 348 178 (51.1) 134 (38.5) 36 (10.3)
PVL yes 18 12 (66.7) 3 (16.7) 3 (16.7) 0.18
no 455 233 (51.2) 173 (38.0) 49 (10.8)
PDA yes 258 144 (55.8) 86 (33.3) 28 (10.9) 0.14
no 215 101 (47.0) 89 (41.4) 25 (11.6)
ROP yes 98 55 (56.1) 33 (33.7) 10 (10.2) 0.54
no 347 173 (49.9) 132 (38.0) 42 (12.1)
ROP or death yes 129 76 (58.9) 40 (31.0) 13 (10.1) 0.13
before screening no 324 157 (48.5) 128 (39.5) 39 (12.0)
Table 6.  Distribution of the CPS1 p.Thr1406Asn polymorphism genotypes in several neonatal outcomes. 
Results are expressed as absolute numbers of patients (percentage) or mean (SD). CC denotes homozygosity 
for the C-encoded CPS1 p.Thr1406Asn polymorphism variant; AA homozygosity for the A-encoded CPS1 
p.Thr1406Asn polymorphism variant; CA heterozygosity for CPS1 p.Thr1406Asn polymorphism. RDS: 
respiratory distress syndrome; BPD: bronchopulmonary dysplasia; IVH: intraventricular hemorrhage (≥ grade 2); 
PVL: periventricular leukomalacia; PDA: patent ductus arteriosus; ROP: retinopathy of prematurity (≥ stage II).
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third week of life33,34, we performed an additional analysis in which the infants with NEC were combined with the 
infants who died before 34 weeks of corrected GA. Interestingly, we observed that the minor A-allele was signif-
icantly less frequent among the infants with the combined outcome NEC or death. Moreover, the dominant and 
additive model demonstrated that the A variant of the p.Thr1406Asn polymorphism significantly decreased the 
risk of developing the combined outcome of NEC or death before 34 weeks of corrected GA. Thus, in other words, 
the minor A variant of the polymorphism might protect against this combined outcome.
In accordance with our results, it has been reported a protective role of the A-allele toward persistent pul-
monary hypertension of the newborn15, pulmonary hypertension following surgical repair of congenital heart 
defects26, and hepatic veno-occlusive disease after bone marrow transplantation23. Moreover, the haplotype 
formed by the SNPs of CPS1 rs715 and rs1047891 (p.Thr1406Asn) yield a protective association with decreased 
risk of coronary artery disease in women35. As mentioned in the introduction, those findings led to the spec-
ulation that individuals with the A-allele may have an advantage in terms of availability of the NOS substrate 
L-arginine, especially under conditions of environmental stress15,23,26. Accordingly, the serum levels of arginine 
were higher in term newborns carrying the AA genotype15. However, activity reports on the in vitro activity of the 
p.Thr1406Asn variants are contradictory22. Thus, natural (A-encoded) Asn1406 CPS has been reported to have 
higher enzymatic activity than the (C-encoded) Thr1406 variant15,23,26 but recombinant Asn1406 CPS1 showed 
inferior catalytic properties36. In order to evaluate whether p.Thr1406Asn genotypes correlated with urea cycle 
intermediates levels in preterm infants, we measured the concentrations of arginine and citrulline in the first 128 
infants included in the present cohort and we did not observe any significant differences28. This lack of effect of 
CPS1 genotype on L-arginine concentrations has been also reported in adults25. Nevertheless, one limitation of 
our study was that L-arginine levels were determined between 6 and 12 hours after birth, whereas NEC has its 
onset later in life33,34. It can be speculated that the alterations in arginine levels related to the p.Thr1406Asn pol-
ymorphism may be only relevant under the stress conditions generated around the time of NEC onset. At that 
moment, being carrier of a genetic variant that potentially increases NO production (i.e., the A-allele) might be of 
critical relevance because NO is a key regulator intestinal blood flow, protector of the mucosa, and modulator of 
the inflammatory response10–12. In addition, the infants homozygous for the C-allele might be more susceptible to 
NEC and arginine supplementation16,20,21 might be particularly indicated in this group.
One limitation of our study is that we did not collect information on the feeding practices. Human milk pro-
tects against NEC1–3 and, although the preterm formulas currently used have concentrations of arginine similar 
to the human milk16, arginine intake might be different depending on the infants diet. Plasma arginine levels are 
likely to represent a balance between arginine intake, arginine synthesis, and the demands of protein synthesis 
and the multiple metabolic pathways for arginine utilization14,37. Enteric arginine synthesis appears to be neces-
sary to cover neonatal requirements, because mammalian milk is a relatively poor source of arginine, whereas its 
precursors proline and glutamine are abundant38. In fact, proline is the major contributor to arginine synthesis in 
human preterm infants39. CPS, ornithine aminotransferase, and argininosuccinate synthetase are key enzymes in 
the control of de novo intestinal synthesis of arginine, which are already expressed in the mid gestation human 
intestine38. However, hypoargininemia often develops in preterm infants, in particular if they are maintained 
on total parenteral nutrition, and it has been suggested that the intestine only produces arginine if substrate is 
supplied through enteral nutrition14,37–39. In situations of reduced availability of the substrate L-arginine or the 
cofactor BH4, NOS enzymatic activity becomes uncoupled, resulting in the production of superoxide instead of 
NO40. Therefore, besides resulting in a paucity of NO, the uncoupled enzyme will generate free radicals resulting 
in further intestinal damage. In addition, it should be taken into account that, besides NO, arginine is a sub-
strate for synthesis of many biologically important molecules including agmatine, polyamines, and creatine14,38,41. 
These metabolites have roles in energy metabolism, gene expression, apoptosis, and cell proliferation and differ-
entiation, which are crucial in intestinal homeostasis14,38,41. Our present results suggest that functional genetic 
variations in the CPS enzyme might be, at least partially, the link between hypoarginimemia and NEC in pre-
term infants14,16–19. Alternatively, recent experimental evidences highlighted the role of argininosuccinate lyase, 
another enzyme involved in the intestinal synthesis of arginine, in the pathogenesis of NEC41.
Concluding remarks. NEC affects only a minority of preterm infants, which suggest an individual suscep-
tibility toward the disease. Genetic polymorphisms might be an important factor in this individual susceptibil-
ity2,4,5,9,42–51. Our study provides further evidence that a functional variant of the CPS1 gene may contribute to 
NEC susceptibility. Nevertheless, NEC is a complex multifactorial disease and an isolated genetic derangement 
may not be sufficient to account for the entire spectrum of its pathophysiology.
Given the importance of prematurity, intestinal function, immune defense, inflammatory signaling, and 
microcirculatory regulation mechanisms, potential variations in many genes could protect or leave a host infant 
susceptible to NEC5,9,42–51. Future studies investigating the association of multiple SNPs and NEC may allow for 
the development of a laboratory genetic test that could predict, when environmental factors are properly assessed, 
the risk/probability of preterm infants developing NEC and lead to more targeted therapies.
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